Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.